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Éva Csősz3, Péter Nagy1, Imre J. Holb4,5, Ralph Rühl6, László Nagy3, Gábor Szabó1 & 
Katalin Goda1
Retinoids – derivatives of vitamin A – are important cell permeant signaling molecules that regulate 
gene expression through activation of nuclear receptors. P-glycoprotein (Pgp) and ABCG2 are plasma 
membrane efflux transporters affecting the tissue distribution of numerous structurally unrelated 
lipophilic compounds. In the present work we aimed to study the interaction of the above ABC 
transporters with retinoid derivatives. We have found that 13-cis-retinoic acid, retinol and retinyl-
acetate inhibited the Pgp and ABCG2 mediated substrate transport as well as the substrate stimulated 
ATPase activity of these transporters. Interestingly, 9-cis-retinoic acid and ATRA (all-trans retinoic acid), 
both are stereoisomers of 13-cis-retinoic acid, did not have any effect on the transporters’ activity. Our 
fluorescence anisotropy measurements revealed that 13-cis-retinoic acid, retinol and retinyl-acetate 
selectively increase the viscosity and packing density of the membrane. Thus, the mixed-type inhibition 
of both transporters by retinol and ABCG2 by 13-cis-retinoic acid may be the collective result of direct 
interactions of these retinoids with the substrate binding site(s) and of indirect interactions mediated 
by their membrane rigidifying effects.
P-glycoprotein (Pgp, MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, MXR, ABCG2) are mem-
bers of the ATP-binding-cassette (ABC) transporter family characterized by their evolutionary conserved 
ATP-binding domains. ABC transporters form one of the largest protein families and are present in every organ-
ism from bacteria to human (for reviews see refs 1, 2, 3). In higher eukaryotes several ABC transporters have 
important functions in drug metabolizing and drug excreting organs, e.g. in the liver and the kidney, and also 
play a role in the formation of tissue barriers, including the intestinal epithelium, blood-brain, blood-placenta 
and blood-testis barriers, suggesting that these proteins are important determinants of the pharmacokinetics of 
various chemotherapeutic compounds4. Since Pgp and ABCG2 is expressed in the apical membrane of entero-
cytes, they affect the intestinal absorption of nutrients, drugs, food additives and xenobiotics5. In addition, over-
expression of Pgp and ABCG2 has also been demonstrated in chemotherapy resistant tumors of various tissue 
origins (for reviews see refs 6, 7, 8, 9). Of note, ABCG2 is also involved in rather specific physiological functions 
e.g. transport of urate10, androgens and estrogens11, while such roles have not yet been identified for Pgp.
A common structural feature of active ABC transporters is that they contain two nucleotide binding domains 
(NBDs) responsible for binding and hydrolysis of ATP and at least two transmembrane domains (TMDs) form-
ing the drug binding pocket and the drug translocation pathway. Pgp and ABCG2 have particularly wide and 
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partially overlapping substrate spectra without any significant sequence similarity in the TMDs of the two trans-
porters12. Mutagenesis studies as well as photoaffinity labeling in conjunction with mass spectrometry suggest 
that the drug-binding pocket of Pgp consists of multiple drug interaction sites located at the interface between 
the two TMDs involving both halves of the protein13–16. Analogously, it seems reasonable that the drug-binding 
pocket of ABCG2 is collectively formed by the TMDs of the dimerizing partners. Based on high-resolution crystal 
structures of Pgp as well as biophysical and biochemical studies, it is suggested that the substrate binding cavity 
is accessible from both the cytoplasm and the inner membrane leaflet17. Similarly to Pgp, ABCG2 also seems to 
export its substrates, like mitoxantrone, directly from the plasma membrane18. Therefore, the extent of partition-
ing of substrates into the membrane is important for their interaction with Pgp and ABCG2, because it essentially 
controls their effective concentration presented to the transporter (for a review see ref. 19).
Retinoids play an essential role in a number of physiological mechanisms including cell survival and tran-
scriptional regulation of cell differentiation and proliferation. Retinol is present in the plasma at 1–2 micromo-
lar concentration20, while its natural metabolites including all-trans retinoic acid (ATRA), 9-cis-retinoic acid or 
13-cis-retinoic acid (isotretionin) are present in the plasma at nanomolar concentrations and can regulate the 
expression of specific genes upon activation of nuclear receptors including RAR-RXR heterodimers, PPARs and 
VDR21–23. Certain retinoid derivatives including ATRA and 13-cis-retinoid acid are used in chemotherapy for 
the treatment of neuroblastoma or squamous cell carcinoma at much higher concentrations resulting in 10–20 
micromolar plasma concentrations24–26. Retinyl-acetate and retinyl-palmitate are widely applied as food additives, 
and are also used as a component of anti-ageing cosmetics27. Retinyl-acetate also seems promising in the treat-
ment of certain degenerative diseases of the retina28. According to literature data certain retinoid derivatives show 
uneven distribution between the placenta and the embryo, raising the possibility that active transporters might 
be involved in their transport29. Since Pgp and ABCG2 are expressed in the placenta, they might have roles in the 
protection of the fetus from xenobiotics and teratogens such as retinoids30.
In this study we aimed to elucidate the interactions of different retinoid compounds of physiological or med-
ical relevance with human multidrug transporter proteins Pgp and ABCG2, to answer the question if they might 
be ligands of these proteins.
Results
Certain retinoids inhibit the drug transport activity of Pgp and ABCG2 in live cells. We have 
studied the effects of retinoids on the transport activity of Pgp and ABCG2 using cell lines expressing these 
pumps at high level, as it is demonstrated by direct immunofluorescence (Fig. 1c). Calcein-AM was applied to 
study the transport function of Pgp, while mitoxantrone was used to visualize ABCG2-mediated transport. Our 
data show that retinol, 13-cis-retinoic acid and retinyl-acetate increased the cellular accumulation of the fluo-
rescent transporter substrates in a concentration dependent manner in Pgp and ABCG2 expressing cells alike 
(Fig. 1a,b). When applied at relatively high concentrations (25–100 μ M, see Fig. 1a,b), the effect of these retinoid 
derivatives was comparable to that of the specific transporter inhibitors, however they did not have any effect on 
the transporter negative cells (Supplementary Fig. S1).
Effect of retinoids on the ATPase activity of Pgp and ABCG2. Since retinoids might be isomerized 
or converted to other retinoid derivatives in live cells31, in further experiments we applied Spodoptera frugiperda 
(Sf9) membrane preparations expressing the examined transporters (see Supplementary Fig. S2). We measured 
the effects of the retinoids on the basal and the substrate-stimulated ATPase activity of the transporters32. Due to 
low expression of endogenous ATPases and high expression of human ABC transporters, the Sf9 cell membrane 
preparations exhibited high specific ATPase activities33. The substrate concentrations required for the maximum 
stimulation were determined: treatment with 40 μ M verapamil brought about a 4-fold stimulation of the ATPase 
activity of Pgp (approximately 20 nmol Pi/mg protein/min), while 10 μ M quercetin induced about a 2-fold stim-
ulation of ABCG2 activity up to 60–70 nmol Pi/ mg protein/min (Fig. 2).
Retinyl-acetate slightly stimulated the basal ATPase activity of Pgp (Fig. 2c, yellow symbols). However, we 
could not demonstrate its Pgp substrate character in cytotoxicity measurements since Pgp+ and Pgp− cells exhib-
ited identical cytotoxicity profile (see Supplementary Fig. S3).
In accordance with the substrate accumulation assays carried out in live cells (Fig. 1), retinyl-acetate ham-
pered the substrate-stimulated ATPase activity of Pgp and ABCG2 (Fig. 2c,f, brown symbols), while retinol and 
13-cis-retinoic acid inhibited both the basal- and the substrate-stimulated ATPase activity of either transporters 
(Fig. 2a,b,d,e). From the dose-response curves, we calculated the IC50 values for the basal and the substrate stim-
ulated ATPase activities as it shown in Fig. 2.
Several other physiological retinoid derivatives including ATRA, 9-cis-retinoic acid, retinyl-propionate and 
retinyl-palmitate were tested in our drug accumulation and ATPase activity measurements, but none of them 
had any effect on the transport or ATPase activity of Pgp and ABCG2 (see Fig. 1 and Supplementary Table S1).
Cellular accumulation of retinoids. 13-cis-retinoic acid and retinol inhibited both Pgp and ABCG2. 
Intriguingly however, ATRA (all-trans retinoic acid) and 9-cis-retinoic acid differing only in the posi-
tion of the cis double bond from 13-cis-retinoic acid did not affect the transporters’ activity. We supposed 
that low membrane partitioning and weak cellular accumulation might be responsible for the lack of effect. 
Although the octanol-water partition coefficient of each retinoid was found to be very high as it is shown in 
Supplementary Table S2, membrane partitioning might also be affected by the shape of the molecules. Since the 
cellular accumulation of drugs is dependent on their membrane partitioning, we estimated the fraction of reti-
noids accumulated by Pgp and ABCG2 negative NIH 3T3 cells (Fig. 3). We have found that the cellular accumu-
lation of the examined Pgp and ABCG2 substrates/modulators and retinoids correlated with their octanol-water 
partition coefficient in a large concentration range (compare the data in Fig. 3 and Supplementary Table S2).
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Effects of retinoids on the fluorescence anisotropy of DPH and TMA-DPH. In view of the strong 
lipophilicity of retinoids (see Supplementary Table S2) as well as the intimate association of Pgp and ABCG2 
with the lipid bilayer in which they are embedded and from which they harvest their substrates, we examined the 
effects of retinoids on the fluidity and packing order of the membrane. We carried out fluorescence anisotropy 
measurements using fluorescent membrane probes, DPH and TMA-DPH. DPH is an apolar molecule that par-
titions into the acyl-chain region of the membrane, while TMA-DPH is a cationic derivative of DPH34. Since its 
positive charge is anchored at the membrane interface the average fluorophore of TMA-DPH is localized closer to 
the membrane surface by about 3–4 Å compared to DPH. Thus, the measured TMA-DPH and DPH fluorescence 
anisotropy values reflect the fluidity and packing order in slightly different depths of the membrane35,36.
The steady-state fluorescence anisotropy of DPH was in the range of 0.14 and 0.18 (Fig. 4a,b), while the flu-
orescence anisotropy of TMA-DPH changed between 0.28 and 0.30 for the different cell lines used in this study 
(Fig. 4c,d). The measured anisotropy values were slightly cell line specific, but independent of the expression of 
the transporters, in accordance with previous data37. Interestingly, retinol, 13-cis-retinoic acid and retinyl-acetate, 
the retinoids that proved capable of Pgp and ABCG2 inhibition, increased the DPH fluorescence anisotropy val-
ues significantly in the case of all tested cell lines, while the other retinoids investigated had no significant effect 
(Fig. 4). Retinol and 13-cis-retinoic acid modified the DPH anisotropy similarly in the transporter expressing and 
non-expressing cell lines suggesting that the presence or activity of the transporters do not affect the distribution 
of these retinoids in the membrane. In contrast, retinyl-acetate had significantly lower effect on the DPH fluo-
rescence anisotropy of the Pgp+ NIH 3T3 MDR1 cell line compared to its Pgp− counterpart (Fig. 4a) apparently 
because of its altered sequestration in the membrane of Pgp expressing cells.
Figure 1. Effect of retinoid derivatives on the transport activity of Pgp (a) and ABCG2 (b) expressed in NIH 
3T3 and MDCK cells, respectively. Cells were pre-treated with retinoids or transporter inhibitors (cyclosporin 
A or Ko143) for 20 min at 37 °C and then the NIH 3T3/NIH 3T3 MDR1 cell line pair was stained with 500 nM 
calcein-AM for 20 min (a), while the MDCK/MDCK ABCG2 cell pair (b) was stained with 5 μ M mitoxantrone 
for 40 min at 37 °C. The calcein or mitoxantrone accumulation of the transporter expressing cells is shown as 
a percentage of that of the transporter negative cells. Mean ± SD values of three independent experiments are 
shown. The expression levels of the transporters were determined by direct immunofluorescence using Alexa 
647 conjugated 15D3 mAb for Pgp and 5D3 mAb for ABCG2 (c). (*significant difference compared to the 
control, P < 0.05 by ANOVA, Holm-Sidac post-hoc analysis).
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The examined retinoids did not affect the TMA-DPH fluorescence anisotropy values except for 
retinyl-palmitate that decreased the TMA-DPH anisotropies significantly in the NIH 3T3 cell pair.
In control experiments neither CsA a competitive Pgp-specific modulator, nor the ABCG2-specific inhibitor 
Ko143 had any effect on the anisotropy values of DPH and TMA-DPH, supporting that they do not affect the 
overall membrane fluidity.
Figure 2. Dose-response curves demonstrating the effects of retinoids on the ATPase activity of Pgp 
and ABCG2. Pgp (a,b,c) and ABCG2 (d,e,f) expressing Sf9 cell membrane preparations were pre-incubated 
with retinoids for 10 min at 37 °C and then further incubated in the presence of 3 mM ATP/Mg2+ for 25 min. 
The substrate-dependent ATPase activity of Pgp was measured in the presence of 40 μ M verapamil, while the 
activity of ABCG2 was induced by 10 μ M quercetin. Representative graphs are shown out of three independent 
experiments performed in triplicates (data points are their means ± SD). Data points were fitted with a four 
parameter sigmoidal dose-response relationship (R2 ≥ 0.98, where R2 is the coefficient of determination; see 
Materials and Methods) to determine the IC50 values. IC50 values are given as means ± SEM from 3 independent 
measurements.
Figure 3. Cellular uptake of retinoids and transporter modulators. Samples containing retinoids or 
transporter inhibitors were incubated with NIH 3T3 cells (1 × 106/ml) for 30 min at 37 °C, then the cells were 
removed by 5 min centrifugation at 400 × g. Cellular uptake of the examined compounds was determined by 
calculating the ratio of the absorbances measured in the supernatants before and after incubation with cells. 
(n = 3, mean ± SD).
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Effects of retinoids on the substrate stimulated ATPase activity of Pgp and ABCG2. The inhib-
itory effect of retinoids observed in the previous experiments may be attributed to the allosteric inhibition of the 
transporter, probably related to structural changes of the membrane brought about by retinoids, or to a compet-
itive mechanism due to direct interaction of retinoids with the substrate binding site(s). In order to resolve the 
above problem we analyzed how the kinetic parameters (KM and vmax) of the substrate stimulated ATPase activity 
are influenced by retinol and 13-cis-retinoic acid, the agents that inhibit both the basal and the substrate stimu-
lated ATPase activities of both transporters. In these experiments the ATPase activity of Pgp was stimulated by 
verapamil, while the activity of ABCG2 was induced by quercetin similarly to the previous experiments shown 
in Fig. 2. Fitting the data points obtained at different verapamil/quercetin concentrations with a modified form 
of the Michaelis-Menten equation we have found that retinol increased the KM and decreased the vmax values of 
both transporters (Figs 5a,c and 6a,b,e,f) supporting a mixed-type transporter inhibition. 13-cis-retinoic acid 
also showed mixed-type transporter inhibition of ABCG2 (Figs 5d and 6g,h), however in case of Pgp it did not 
induce statistically significant KM increase while decreased the vmax (Figs 5b and 6c,d), suggesting that it inhibits 
Pgp only non-competitively.
Discussion
We have shown that retinol, 13-cis-retinoic acid and retinyl-acetate inhibited both the Pgp- and ABCG2-mediated 
substrate transport (Fig. 1). Because of the difficulty of directly assessing the binding and transport of highly lipo-
philic drugs by membrane transporters19, the interaction of retinoids with Pgp and ABCG2 was further studied 
in ATPase activity measurements. In these experiments we have found that retinyl-acetate slightly stimulated the 
basal ATPase activity of Pgp (Fig. 2) raising the possibility that it is a transport substrate of Pgp. In accordance 
with it our DPH anisotropy measurements also indicated altered membrane distribution of retinyl-acetete in 
Pgp+ cells (Fig. 4a). However, we observed identical cytotoxicity profile of retinyl-acetate in Pgp+ and Pgp− cells 
(see Supplementary Fig. S3), suggesting that even if it interacts with Pgp as a substrate, the transporter cannot 
cope with its passive influx.
Of note, 13-cis-retinoic acid inhibited both Pgp and ABCG2, while its stereoisomer ATRA (all-trans retinoic 
acid) and 9-cis-retinoic acid differing only in the position of the cis double bond did not affect the transport-
ers’ activity (see Figs 1 and 2 and Supplementary Table S1). In view of the wide substrate spectrum of Pgp and 
Figure 4. Effects of retinoids on the DPH (a,b) and TMA-DPH (c,d) fluorescence anisotropies in Pgp+ and 
Pgp− NIH 3T3 cells (a,c), and ABCG2 expressing and non-expressing MDCK cells (b,d). Cells were pre-treated 
with retinoids applied at 100 μ M concentration or transporter inhibitors (10 μ M cyclosporin (for Pgp) or 2 μ M 
Ko143 (for ABCG2)) for 10 min at 37 °C and then further incubated with 2 μ M DPH or TMA-DPH for another 
20 min at room temperature. Fluorescence anisotropy values were measured at 37 °C. (*significant difference 
compared to control, †significant difference between drug-sensitive and -resistant cells (n = 3, mean ± SD, 
ANOVA, Holm-Sidac post-hoc analysis, P < 0.05)).
www.nature.com/scientificreports/
6Scientific RepoRts | 7:41376 | DOI: 10.1038/srep41376
ABCG2, this stereospecific interaction is striking and might provide further insight into the working mechanism 
of these transporters. In line with our observations, stereoisomers of a cyclic oligopeptide interact differently 
with Pgp based on crystallography data and homology modeling: QZ59-RRR binds at only one site located at 
the center of the Pgp molecule between TM6 and TM12, while its stereoisomer QZ59-SSS binds at two sites per 
Pgp38. Similarly, stereo-chemical differences have been observed in the case of the interaction of cis- and trans- 
stereoisomers of flupentixol with Pgp. Both stereoisomers of flupentixol inhibit Pgp-mediated drug transport and 
reverse drug resistance. They have equal binding affinity to Pgp, but they have opposite effects on the rate of ATP 
hydrolysis and photo affinity labeling of Pgp with the substrate analogue [125I]IAAP39. Taken together, previous 
studies established stereospecific differences between ligands in their mode of interaction with Pgp. In contrast, 
we observed that the recognition of certain retinoid derivatives by Pgp and ABCG2 is stereo-selective.
Stereo-selective recognition of the ligands might occur at the level of the drug binding sites or allosteric sites of 
the transporters or alternatively, at the level of the plasma membrane from where the substrates and modulators 
probably reach the drug binding site(s). The lipophilicity of the stereoisomers based on their octanol-water parti-
tion coefficients (LogPow, see Supplementary Table S2) is similarly high and they exhibit strong cellular accumu-
lation (Fig. 3) that correlates with their LogPow, thus different extent of partitioning into the membrane does not 
seem to explain their behavior. However, distinct intramembrane localization of the stereoisomers may explain 
their different behavior. In agreement with this idea, Widomska and Subczynski have demonstrated that cis and 
trans isomers of zeaxanthin have different orientations in dimyristoyl phosphatidylcholine bilayer membranes 
and thus can modify the biophysical membrane properties, including the hydrophobicity and membrane fluidity 
at different depth of the membrane40. In accordance with this report our fluorescence anisotropy measurements 
revealed that the retinoid derivatives interacting with the transporters retinyl-acetate, 13-cis-retinoic acid and 
retinol selectively increase the membrane viscosity and packing density in the depth of the membrane monitored 
by DPH, while ATRA and 9-cis-retinoic acid did not have any effect (Fig. 4). These results imply that the trans-
membrane orientation of the retinoic acid stereoisomers is different, probably because the net length of their 
isoprene tail varies depending on the presence and position of the kink introduced by the cis double bond. This 
observation is in agreement with recent publications that emphasize the role of membrane-mediated substrate 
and modulator interactions in the determination of the substrate spectrum of Pgp and ABCG241.
To further analyze the interaction of retinoids with the transporters we studied their effects on the kinetic 
parameters of the substrate stimulated ATPase activity. For stimulation of ATPase activity we applied verapa-
mil42,43 and quercetin44 that are real transported substrates of Pgp and ABCG2, respectively. Thus, in these 
experiments changes of the kinetic parameters in response to retinoids really reflect alterations in verapamil 
Figure 5. Inhibition of the substrate stimulated ATPase activity of Pgp and ABCG2 by retinol and 13-cis-
retinoic acid. The ATPase activity of Pgp (a,b) and ABCG2 (c,d) was stimulated by 40 μ M verapamil and 10 μ M  
quercetin, respectively. Representative data are shown out of three independent experiments performed in 
triplicate (data points are means ± SD). The curves were obtained by fitting the data points with a modified form 
of the Michaelis-Menten equation (see Materials and Methods, (R2 ≥ 0.98)).
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and quercetin binding and/or transport by the transporters. The apparent increase of the KM values of verapamil 
and quercetin (Figs 5 and 6 and Supplementary Fig. S4) in the presence of retinol and 13-cis-retinoic acid indi-
cates direct interaction of retinol with both transporters and of 13-cis-retinoic acid with ABCG2. In addition, 
retinol and 13-cis-retinoic acid also decreased the vmax value of both transporters that might be either the result 
of non-competitive inhibition or of decreased effective concentration of the substrates (verapamil/quercetin) in 
the membrane. Non-competitive inhibition might be conveyed either by the binding of retinoids to an allosteric 
site of the transporter, or alternatively, brought about by the membrane rigidifying effect of retinoids. The latter 
explanation is in line with previous findings suggesting that lipid composition and membrane packing density 
in particular, can alter the function of Pgp probably by decreasing its conformational flexibility45,46. In addition, 
structural changes of the membrane may have an influence on the membrane partitioning and distribution of 
Pgp and ABCG2 substrates and thus their effective concentration in the vicinity of the drug binding site(s)47 (for 
a review see ref. 19). However, much further work will be required to fully understand these details.
In respect to the physiological relevance of our results, it seems unlikely that retinoids inhibit the examined 
ABC transporters expressed at various blood-tissue barriers, since their physiological tissue and blood concentra-
tion is in the nanomolar range (1–20 nM)48. However, retinoid therapy or retinol supplementation may result in 
sufficiently high local retinoid concentrations in the blood24–26,49, or in case of oral administration in the intestine 
that may block Pgp and ABCG2 expressed at organ-blood barriers or in the intestinal epithelium. Inhibition of 
the transporters may also affect the pharmacokinetics of other co-administered chemotherapeutic drugs. The 
above effects should be considered upon therapeutic application of retinoids to avoid drug-drug interactions 
occurring at the level of the membrane transporters, Pgp and ABCG2.
In conclusion, the different intramembrane orientation of certain retinoid stereoisomers might be important 
in their selective recognition by Pgp and ABCG2.
Materials and Methods
Chemicals. All chemicals, cell culture media and supplements were purchased from Sigma-Aldrich 
(Budapest, Hungary) except for all-trans-4-oxo-retinoic acid, which was kindly provided by DSM Nutritional 
products (Basel, Switzerland). Fluorescent dyes including calcein acetoxymethyl ester (calcein-AM) and Alexa 
647 succinimidyl ester were purchased from Life Technologies, Inc. (Carlsbad, CA, USA). 5D3 and 15D3 mAbs 
were prepared from hybridoma supernatants using affinity chromatography and were > 97% pure by SDS/PAGE. 
The 15D3 producing hybridoma cell line was obtained from the American Type Culture Collections (Manassas, 
VA, USA), while the 5D3 hybridoma was a kind gift from Brain P. Sorrentino (Division of Experimental 
Hematology, Department of Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, 
USA). The 5D3 and 15D3 antibodies were labeled with Alexa 647 succinimidyl ester (A647) and separated from 
the unconjugated dye by gel filtration on a Sephadex G-50 column. The dye-to-protein labeling ratio was around 
Figure 6. Changes of apparent KM and vmax values of the Pgp- (a–d) and ABCG2-mediated (e–h) ATPase 
activity in response to retinol and 13-cis-retinoic acid treatment. The apparent KM and vmax values were obtained 
by curve-fitting to a modified form of the Michaelis-Menten equation (see Materials and Methods). The ATPase 
activity of Pgp (a,b,c and d) and ABCG2 (e,f,g and h) was stimulated by 40 μ M verapamil and 10 μ M quercetin, 
respectively. (*Significant difference compared to control (n = 3, mean ± SEM, ANOVA, Holm-Sidac post-hoc 
analysis, P < 0.05)).
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3 for each antibody preparation. Stock solutions of lipophilic transporter substrates, modulators including 
calcein-AM, mitoxantrone, cyclosporin quercetin and retinoid derivatives were prepared in dimethyl-sulfoxide 
(DMSO). The final DMSO concentration in the samples was always less than 1% (v/v), and it did not have any 
effect on the transporters activity.
Cell lines. The NIH 3T3 mouse fibroblast cell line and its human Pgp expressing counterpart (NIH 3T3 
MDR1 G18550; kind gift from Michael Gottesman (National Institutes of Health, Bethesda, MD)) and the MDCK 
(Madin-Darby canine kidney) cell line and its ABCG2 transfected counterpart (kindly provided by Balazs Sarkadi 
(Institute of Enzymology, RCNS, Budapest)) were grown as monolayer cultures in Dulbecco’s modified Eagle’s 
medium (DMEM). Cell culture media were supplemented with 10% heat-inactivated fetal calf serum, 2 mM 
L-glutamine and 0.1 mg/ml penicillin-streptomycin cocktail. The cells were checked regularly for mycoplasma 
infection by the MycoAlert® mycoplasma detection kit (Lonza Rockland Inc., Rockland, ME USA) and were 
found to be negative.
Calcein and mitoxantrone accumulation tests. Calcein-AM was applied to measure the transport 
activity of Pgp51, while ABCG2 mediated transport was measured in mitoxantrone accumulation tests18. Cells 
were harvested and washed three times in PBS containing 7 mM glucose (gl-PBS). Cells (0.5 × 106 ml−1 in gl-PBS) 
were pre-incubated in the presence or absence of the tested retinoids at different concentrations or specific inhib-
itors of Pgp (10 μ M cyclosporin CsA) or ABCG2 (2 μ M Ko143) for 20 min at 37 °C and then stained with 5 μ M 
mitoxantrone for 40 min or 0.5 μ M calcein-AM for another 20 min. The samples were washed three times with 
ice-cold PBS containing 0.5% FBS and kept on ice until flow cytometric measurement. Dead cells were excluded 
from the analysis on the basis of propidium iodide (PI) staining.
Direct immunofluorescence. For detection of Pgp and ABCG2 cells (106 ml−1 in gl-PBS) were incubated in 
the presence of 30 μ g/ml Alexa647 conjugated 15D3 anti-Pgp mAb or 2 μ g/ml 5D3 anti-ABCG2 mAb for 30 min 
at 37 °C. After two washes with ice-cold gl-PBS containing 1% bovine serum albumin (BSA-gl-PBS) expression 
levels of the transporters were measured by flow cytometry.
Flow cytometry. Flow cytometric analysis was carried out on a Becton Dickinson FACSAria III Cell Sorter 
(Becton Dickinson, Mountain View, CA, USA). Calcein was excited by the 488 nm line of a solid state laser and 
the emitted light was detected using a 502 nm dichroic mirror and a 530/30 nm band-pass filter. PI was excited by 
the 562 nm line of a solid state laser and the emitted light was detected applying a 590 nm dichroic mirror and a 
595/50 nm band-pass filter. AlexaFluor647 and mitoxantrone signals were detected with a 633 nm excitation laser 
and a 660/20 nm band-pass filter. Fluorescence signals were collected in logarithmic mode and the cytofluori-
metric data were analyzed by the BDIS CELLQUEST (Becton Dickinson, Mountain View, CA, USA) software.
Membrane preparations. For ATPase activity measurements we used membrane samples derived from 
Sf9 (Spodoptera frugiperda) insect ovarian cells expressing human Pgp or ABCG2. cDNAs of the transport-
ers were cloned into recombinant baculovirus transfer vectors, the Sf9 insect ovarian cells were cultured, and 
infected with the baculoviruses as described in ref. 52. Sf9 cells overexpressing human Pgp and ABCG2 were 
harvested and cell membranes were isolated. The protein concentration of the membrane samples were deter-
mined by the Lowry method53. The ABCG2 expressing Sf9 membrane samples were loaded with cholesterol 
by cholesterol-methyl-beta-cyclodextrine complex in order to obtain high specific ATPase activity of the trans-
porter54. Membrane samples were stored at − 80 °C. The transporter expression of the membrane samples (5 μ g 
membrane protein/slot) was routinely checked by immunoblot using the G-1 mAb (for Pgp) or BXP-21 mAb (for 
ABCG2) and a goat anti-mouse HRP-conjugated IgG secondary antibody. Both primary and secondary antibod-
ies were from Santa Cruz Biotechnology Inc. (CA, USA) and applied at 1:5,000 dilution.
ATPase activity measurements. The vanadate-sensitive ATPase activity of Pgp and ABCG2 was deter-
mined by a colorimetric assay described in refs 32,55. Specific ATPase activity of the transporters was calculated 
from the amount of released inorganic phosphate. The substrate dependent ATPase activity was stimulated by 
40 μ M verapamil in the Pgp expressing membrane samples, while the activity of ABCG2 transporters was induced 
by 10 μ M quercetin. The absorbance of the samples was measured at 700 nm using a BioTek Synergy HT plate 
reader (BioTek Instruments, Winooski, USA).
The half-inhibitory doses (IC50) of retinoids were determined by fitting the dose-response relationships with a 
four parameter sigmoidal curve, where Amax and Amin are the ATPase activities measured at zero and at infinitely 
high inhibitor concentrations, respectively, n is the Hill coefficient and x is the concentration of the inhibitor:
= +
+
+ −
y A A A
1 10 (1)min
max min
lgx lgIC n( )50
Upon studying the kinetics of inhibition of the substrate-stimulated ATPase activity by retinoids data points 
were fitted with a modified form of the Michaelis-Menten equation56 which includes the Hill coefficient, n:
=
+ − ⋅
+
v v v v S
S K
( )
(2)
max
n
n
M
0 0
v0 is the basal ATPase activity measured in the absence of the stimulatory substrate, while vmax is the maximal 
extent of ATPase stimulation and KM is the Michaelis constant (i.e. the substrate concentration at which the reac-
tion rate is half of vmax).
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Cellular uptake of retinoids and transporter inhibitors. NIH 3T3 mouse fibroblast cells (1 × 106 cells/ml 
in gl-PBS containing 1% BSA were incubated with retinoids or transporter ligands (quercetin, cyclosporin Ko143) 
applied at different concentrations (1, 10 and 100 μ M) for 30 min at 37 °C. After incubation the cells were removed 
by centrifugation at 400 × g. The cellular uptake of the examined compounds was determined by calculating the 
ratio of the absorbances measured in the supernatants at their absorption maximum before and after incubation 
with cells. Absorbances were determined using a NanoDrop 1000 UV/VIS Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE, USA).
Fluorescence anisotropy measurements. Cells (1 × 106 cells/ml in Hank’s buffer (0.137 M NaCl, 5.4 mM 
KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3, 7 mM glucose)) 
were pre-treated with 100 μ M retinoid derivative for 10 min at 37 °C and then further incubated with 2 μ M diphe-
nylhexatriene (DPH) or 2 μ M 1-[4-(trimethylammonio)phenyl]-6-phenyl-1,3,5-hexatriene (TMA-DPH) at room 
temperature, in dark for 20 min. Steady-state fluorescence anisotropy measurements were carried out at 37 °C 
using a Horiba Jobin Yvon Fluorolog-3 (Yvon Horiba, Edison, NJ, USA) spectrofluorimeter equipped with a 
thermostatted cell holder. The fluorescence of DPH and TMA-DPH was excited at 358 nm and their emission 
was measured at 427 nm. The steady-state fluorescence anisotropy of the dyes was calculated using the formula:
=
−
+
r I GI
I GI2 (3)
VV VH
VV VH
where, IVV and IVH are the vertically and horizontally polarized components of the fluorescence intensities, 
respectively, excited by vertically polarized light and G is a correction factor compensating for the unequal sen-
sitivity of the detection system for vertically and horizontally polarized light. There is an inverse correlation 
between membrane fluidity and fluorescence anisotropy: the lower the anisotropy value, the higher the mem-
brane fluidity; hence, the increase of fluorescence anisotropy is indicative of lower fluidity and higher structural 
order within the membrane35.
Statistical analysis. Data were analyzed using SigmaStat (version 3.1, SPSS Inc., Chicago, IL, USA) and are 
presented as means ± SD. Comparison of two groups was carried out by unpaired t-test, statistical significance 
in the case of three or more groups was assessed using analysis of variance (ANOVA), applying the Holm-Sidak 
multiple comparison test for post hoc pair-wise comparison of the data. Differences were considered significant 
at P < 0.05. Dose-response curves were fitted using SigmaPlot 12.0 (SPSS Inc., Chicago, IL, USA).
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